Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In non-pathological conditions the clearance of cerebral Aβ exceeds its production [9].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [9]
In the citing paper
“we adapted an in vivo stable isotopic labeling kinetics technique previously described in humans (43).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [43]
In the citing paper
“which is approximately 4-times slower than the turnover rate for the total CNS Aβ peptide (Fig. 6) [31]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [31]
In the citing paper
“The interstitial concentration of Aβ is higher in awake than in sleeping rodents and humans”
From Sleep Drives Metabolite Clearance from the Adult Brain (2013) · cites this paper as [15]
In the citing paper
“In prior SILK studies (19), plasma 13C6-leucine enrichment was found to adequately represent 13C6 labeling in the precursor pool for Aβ synthesis.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several earlier studies have shown that some plasma Aβ can enter the CN”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“In Down syndrome, three copies of APP result in increased production of Aβ, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref”
Garlick, P. J., McNurlan, M. A., & Preedy, V. R. (1980) · Biochemical Journal · doi:10.1042/bj1920719 · Cited by 973
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Cerebrospinal Fluid in Diseases of the Nervous System.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 657
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Cited by
Items 201–300 of 627
PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier
Mazura, A. D., Ohler, A., Storck, S. E., Kurtyka, M., Scharfenberg, F., Weggen, S., Becker-Pauly, C., & Pietrzik, C. U. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04237-x · Cited by 59
“In nonpathological conditions the clearance of cerebral Aβ exceeds its production [9].”
BackgroundAntila, S., Chilov, D., Nurmi, H. J., Li, Z., Näsi, A., Gotkiewicz, M., Sitnikova, V., Jäntti, H., Acosta, N., Koivisto, H., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00445-9 · Cited by 55
A role for sleep disorders in pregnancy complications: challenges and opportunities
Romero, R. J., & Badr, M. S. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.11.020 · Cited by 57
Cho, G. M., Lee, S., Park, J. H., Kim, M. J., Park, K.-J., Choi, B. T., Shin, Y., Kim, N. G., & Shin, H. K. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly240 · Cited by 63
Ishida, K., Misawa, K., Nishimura, H., Hirata, T., Yamamoto, M., & Ota, N. (2020) · Nutrients · doi:10.3390/nu12020494 · Cited by 56
Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
Selnes, P., Blennow, K., Zetterberg, H., Grambaite, R., Rosengren, L., Johnsen, L., Stenset, V., & Fladby, T. (2010) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-7-10 · Cited by 52
Targeted proteomics in Alzheimer’s disease: focus on amyloid-β
Portelius, E., Zetterberg, H., Gobom, J., Andreasson, U., & Blennow, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.225 · Cited by 51
The use of mass spectrometry to study amyloid‐β peptides
Grasso, G. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20281 · Cited by 57
Tong, M., Arora, K., White, M. M., & Nichols, R. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.241299 · Cited by 54
Chai, A. B., Hartz, A. M. S., Gao, X., Yang, A., Callaghan, R., & Gelissen, I. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010246 · Cited by 54
Liu, D., Li, W., Jiang, X., Bai, S., Liu, J., Liu, X., Shi, Y., Kuai, Z., Kong, W., Gao, R., et al. (2019) · Theranostics · doi:10.7150/thno.30649 · Cited by 49
Slats, D., Claassen, J. A. H. R., Spies, P. E., Borm, G. F., Besse, K., van Aalst, W., Tseng, J., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.07.008 · Cited by 54
Shackleton, B., Crawford, F., & Bachmeier, C. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0038-x · Cited by 45
de Dios, C., Bartolessis, I., Roca-Agujetas, V., Barbero-Camps, E., Mari, M., Morales, A., & Colell, A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101283 · Cited by 47
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 50
Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease
Kalaria, R. N. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.020 · Cited by 48
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
Kron, J. O.-Z. J., Keenan, R. J., Hoyer, D., & Jacobson, L. H. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-031929 · Cited by 52
Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 53
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β-Peptide(1–40)
Shi, H., Kang, B., & Lee, J. Y. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b08685 · Cited by 47
Foidl, B. M., & Humpel, C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00113 · Cited by 47
Bales, K. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.666234 · Cited by 45
Patel, P., & Shah, J. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.007 · Cited by 46
Endothelins in inflammatory neurological diseases
D’Orléans-Juste, P., Ndunge, O. B. A., Desbiens, L., Tanowitz, H. B., & Desruisseaux, M. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.001 · Cited by 46
Steele, J. W., Kim, S. H., Cirrito, J. R., Verges, D. K., Restivo, J. L., Westaway, D., Fraser, P., Hyslop, P. S. G., Sano, M., Bezprozvanny, I., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-51 · Cited by 44
Self-citationAfsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β-Peptide(1–42)
Shi, H., & Lee, J. Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00375 · Cited by 44
Michno, W., Stringer, K. M., Enzlein, T., Passarelli, M. K., Escrig, S., Vitanova, K. S., Wood, J. I., Blennow, K., Zetterberg, H., Meibom, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg4855 · Cited by 54
Therapeutic effects of phlorotannins in the treatment of neurodegenerative disorders
Kwon, S. Y., Kwon, O. I., Hwang, H. J., Shin, H., & Yang, S. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1193590 · Cited by 45
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes
Miners, J. S., Palmer, J. C., Tayler, H. M., Palmer, L. E., Ashby, E. L., Kehoe, P. G., & Love, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00238 · Cited by 50
CNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition
Dobrowolska, J. A., Michener, M. S., Wu, G., Patterson, B. W., Chott, R., Ovod, V., Pyatkivskyy, Y., Wildsmith, K. R., Kasten, T., Mathers, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0540-14.2014 · Cited by 37
Self-citationSingh, S. A., Andraski, A. B., Pieper, B., Goh, W., Mendivil, C. O., Sacks, F. M., & Aikawa, M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.d061432 · Cited by 42
Sex Hormone Decline and Amyloid β Synthesis, Transport and Clearance in the Brain
Duarte, A. C., Hrynchak, M. V., Gonçalves, I., Quintela, T., & Santos, C. R. A. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12432 · Cited by 45
The Role of Apolipoprotein E Isoforms in Alzheimer’s Disease
Roda, A. R., Montoliu-Gaya, L., & Villegas, S. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180740 · Cited by 39
Tokgöz, S., & Claassen, J. A. H. R. (2021) · Cardiology and Therapy · doi:10.1007/s40119-020-00209-z · Cited by 42
Madadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
Light sheet fluorescence microscopy of optically cleared brains for studying the glymphatic system
Bèchet, N. B., Kylkilahti, T. M., Mattsson, B., Petrášová, M., Shanbhag, N. C., & Lundgaard, I. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20924954 · Cited by 44
Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 41
Metallostasis and amyloid β-degrading enzymes
Grasso, G., Giuffrida, M. L., & Rizzarelli, E. (2012) · Metallomics · doi:10.1039/c2mt20105d · Cited by 43
Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Rotello, R. J., & Veenstra, T. D. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200921153513 · Cited by 42
Lazarev, V. F., Tsolaki, M., Mikhaylova, E. R., Benken, K. A., Shevtsov, M. A., Nikotina, A. D., Lechpammer, M., Mitkevich, V. A., Makarov, A. А., Moskalev, A., et al. (2021) · Aging and Disease · doi:10.14336/ad.2020.1230 · Cited by 41
Dubey, S., & Singh, E. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01173-5 · Cited by 39
Ortega, F., Stott, J., Visser, S. A. G., & Bendtsen, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.419135 · Cited by 37
Future Prospects for Biomarkers of Alcohol Consumption and Alcohol‐Induced Disorders
Freeman, W. M., & Vrana, K. E. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01169.x · Cited by 44
Zheng, S., McIntosh, T. S., & Wang, W. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.357 · Cited by 41
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
Quantitation of Human Peptides and Proteins Via MS: Review of Analytically Validated Assays
Chappell, D. L., Lassman, M. E., McAvoy, T., Lin, M., Spellman, D. S., & Laterza, O. (2014) · Bioanalysis · doi:10.4155/bio.14.145 · Cited by 40
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology
Li, T. R., Chatterjee, M. S., Lala, M., Abraham, A. K., Freshwater, T., Jain, L., Sinha, V. P., de Alwis, D. P., & Mayawala, K. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2170 · Cited by 39
Sharma, H. S., Muresanu, D. F., Lafuente, J. V., Patnaik, R., Tian, Z. R., Ozkızılcık, A., Castellani, R. J., Mössler, H., & Sharma, A. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0742-9 · Cited by 37
RetractedNeubert, H., Song, A., Lee, A., Wei, C., Duggan, J., Xu, K., Woolf, E., Evans, C., Palandra, J., Laterza, O., et al. (2017) · Bioanalysis · doi:10.4155/bio-2017-4973 · Cited by 37
Gao, H., Liu, M., Zhao, Z., Yang, C., Zhu, L., Cai, Y., Yang, Y., & Hu, Z. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c00370 · Cited by 40
Metabolite Clearance During Wakefulness and Sleep
Hladky, S. B., & Barrand, M. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_37 · Cited by 39
Lu, Y., Riddell, D. R., Hajós‐Korcsok, É., Bales, K. R., Wood, K. M., Nolan, C. E., Robshaw, A., Zhang, L., Leung, L. Y., Becker, S. L., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192625 · Cited by 35
Why therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 39
Practical Immunoaffinity-Enrichment LC-MS for Measuring Protein Kinetics of Low-Abundance Proteins
Lassman, M. E., McAvoy, T., Lee, A. Y. H., Chappell, D. L., Wong, O., Zhou, H., Reyes‐Soffer, G., Ginsberg, H. N., Millar, J. S., Rader, D. J., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.222455 · Cited by 34
Kanodia, J., Gadkar, K. G., Bumbaca, D., Zhang, Y., Tong, R., Luk, W., Hoyte, K., Lu, Y., Wildsmith, K., Couch, J., et al. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12081 · Cited by 40
Stable Isotope Labeling with Amino Acids in Drosophila for Quantifying Proteins and Modifications
Xu, P., Tan, H., Duong, D. M., Yang, Y., Kupsco, J., Moberg, K. H., Li, H., Jin, P., & Peng, J. (2012) · Journal of Proteome Research · doi:10.1021/pr300613c · Cited by 33
Hawkins, J., Harrison, D. C., Ahmed, S. F., Davis, R. P., Chapman, T. D., Marshall, I., Smith, B. B., Mead, T. L., Medhurst, A. D., Giblin, G. M. P., et al. (2011) · Neurodegenerative Diseases · doi:10.1159/000324511 · Cited by 36
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Tian, Z. R., Ozkızılcık, A., Manzhulo, I., Mössler, H., & Sharma, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.009 · Cited by 34
Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease
Kang, H., Shin, H. J., An, H. S., Jin, Z. H., Lee, J. Y., Lee, J., Kim, K. E., Jeong, E. A., Choi, K. Y., McLean, C., et al. (2021) · Antioxidants · doi:10.3390/antiox10111657 · Cited by 38
Harrass, S., Yi, C., & Chen, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011207 · Cited by 34
Effect of human cerebrospinal fluid sampling frequency on amyloid‐β levels
Li, J., Llano, D. A., Ellis, T. A., LeBlond, D. J., Bhathena, A., Jhee, S. S., Ereshefsky, L., Lenz, R. A., & Waring, J. F. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.900 · Cited by 38
Malgieri, G., & Grasso, G. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.10.008 · Cited by 35
Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy
Jennum, P., Pedersen, L. Ø., Bahl, J. M. C., Modvig, S., Fog, K., Holm, A., Kornum, B. R., & Gammeltoft, S. (2016) · SLEEP · doi:10.1093/sleep/zsw006 · Cited by 39
Downregulation of serum miR-106b: a potential biomarker for Alzheimer disease
Madadi, S., Saidijam, M., Yavari, B., & Soleimani, M. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1734842 · Cited by 36
Alzheimer's disease: γ-secretase inhibitors
Imbimbo, B. P. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.10.002 · Cited by 32
Lucey, B. P., Gonzales, C., Das, U., Li, J., Siemers, E., Slemmon, J. R., Bateman, R. J., Huang, Y., Fox, G. B., Claassen, J. A. H. R., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0136-z · Cited by 35
Self-citationWildburger, N. C., Gyngard, F., Guillermier, C., Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Schneider, T., Green, K., Roth, R. A., Schmidt, R. E., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00169 · Cited by 33
Self-citationMethod for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry
Wildsmith, K. R., Han, B., & Bateman, R. J. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.07.049 · Cited by 31
Self-citationAging and APOE ‐ε4 are determinative factors of plasma A β 42 levels
Nakamura, T., Kawarabayashi, T., Seino, Y., Hirohata, M., Nakahata, N., Narita, S., Itoh, K., Nakaji, S., & Shoji, M. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.635 · Cited by 32
The Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 32
Dementia and Alzheimer's disease: A new direction. The 2010 Jay L. Foster Memorial Lecture
Kuller, L. H., & López, O. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.901 · Cited by 36
Feng, C., Yin, J., Yang, J., & Cao, L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.12.017 · Cited by 31
Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00121.x · Cited by 30
Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys
Kavanagh, K., Day, S. M., Pait, M. C., Mortiz, W. R., Newgard, C. B., Ilkayeva, O., McClain, D. A., & Macauley, S. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00843 · Cited by 32
Mehta, T. K., Dougherty, J. J., Wu, J., Choi, C. H., Khan, G. M., & Nichols, R. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06070.x · Cited by 30
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
Mapping ApoE/Aβ binding regions to guide inhibitor discovery
Liu, Q., Wu, W.-H., Fang, C.-L., Li, R.-W., Liu, P., Lei, P., Hu, J., Sun, X., Zheng, Y.-Z., Zhao, Y.-F., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05019b · Cited by 30
Zeng, Y., & Han, X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05481.x · Cited by 30
Guarnieri, L., Bosco, F., Leo, A., Citraro, R., Palma, E., Sarro, G. D., & Mollace, V. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102210 · Cited by 30
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 31
Lee, A. Y. H., Yates, N. A., Ichetovkin, M., Deyanova, E. G., Southwick, K., Fisher, T. S., Wang, W., Loderstedt, J., Walker, N. D., Zhou, H., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172429 · Cited by 29
Forest, K. H., Alfulaij, N., Arora, K., Taketa, R., Sherrin, T., Todorovic, C., Lawrence, J. L. M., Yoshikawa, G. T., Ng, H. L., Hruby, V. J., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14257 · Cited by 33
Microvessel occlusions alter amyloid-beta plaque morphology in a mouse model of Alzheimer’s disease
Zhang, Y., Bander, E. D., Lee, Y., Muoser, C. A., Schaffer, C. B., & Nishimura, N. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19889092 · Cited by 29
Basak, J. M., Kim, J., Pyatkivskyy, Y., Wildsmith, K. R., Jiang, H., Parsadanian, M., Patterson, B. W., Bateman, R. J., & Holtzman, D. M. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-14 · Cited by 30
Self-citationAlzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
“colleagues have measured the rate of production and clearance of Aβ (Bateman et al., 2006).”
BackgroundAlzheimer's disease drug development: translational neuroscience strategies
Cummings, J. L., Banks, S. J., Gary, R. K., Kinney, J. W., Lombardo, J. M., Walsh, R. R., & Zhong, K. (2013) · CNS Spectrums · doi:10.1017/s1092852913000023 · Cited by 30
Garbarino, S., & Lorenzi, M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117980 · Cited by 27
Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
Eide, P. K., Lashkarivand, A., Pripp, A. H., Valnes, L. M., Hovd, M. H., Ringstad, G. A., Blennow, K., & Zetterberg, H. (2023) · Brain Communications · doi:10.1093/braincomms/fcad343 · Cited by 29
Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang
Feygina, E. E., Katrukha, A., & Semenov, A. G. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919110105 · Cited by 27
Ashrafizadeh, M., Zarrabi, A., Najafi, M., Samarghandian, S., Mohammadinejad, R., & Ahn, K. S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6732 · Cited by 28
Ford, M. J., Cantone, J. L., Polson, C. T., Toyn, J. H., Meredith, J. E., & Drexler, D. M. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.11.019 · Cited by 26
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26
Self-citationEzpeleta, J., Baudouin, V., Arellano-Anaya, Z. E., Boudet-Devaud, F., Pietri, M., Baudry, A., Haeberlé, A., Bailly, Y. J. R., Kellermann, O., Launay, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11333-3 · Cited by 27
The amyloid cascade hypothesis and Alzheimer’s disease: A mathematical model
Bertsch, M., Franchi, B., Meacci, L., Primicerio, M., & Tesi, M. C. (2020) · European Journal of Applied Mathematics · doi:10.1017/s0956792520000339 · Cited by 25
Mass Spectrometry Imaging in Alzheimer's Disease
Ikegawa, M., Kakuda, N., Miyasaka, T., Toyama, Y., Nirasawa, T., Minta, K., & Hanrieder, J. (2023) · Brain Connectivity · doi:10.1089/brain.2022.0057 · Cited by 27
Understanding HDL Metabolism and Biology Through In Vivo Tracer Kinetics
Andraski, A. B., Sacks, F. M., Aikawa, M., & Singh, S. A. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319742 · Cited by 25
Effects of medications on plasma amyloid beta (Aβ) 42: Longitudinal data from the VITA cohort
Blasko, I., Jungwirth, S., Jellinger, K. A., Kemmler, G., Krampla, W. W., Weissgram, S., Wichart, I., Tragl, K. H., Hinterhuber, H., & Fischer, P. A. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.010 · Cited by 25
Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 26
Metadata
- Authors
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Venue
- Nature Medicine
- Published
- 2006-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 856-861
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2983090
- OpenAlex
- W2171259749
- Cited by
- 599
- References
- 41
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 33 · 2023: 27 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 34 · 2018: 23 · 2017: 35 · 2016: 36 · 2015: 40 · 2014: 31 · 2013: 30 · 2012: 40
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- American Academy of Neurology
- National Institutes of Health (5p41rr000954-34)
- National Institute on Aging (L30 AG024455, K08AG027091, P 50 AG05681, P50AG005681)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 056341, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-000954, M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, cerebrospinal fluid, amyloid precursor protein, biomarkers
- MeSH terms
- Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Protein Conformation, Biomarkers, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.